Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $180,122.24 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 14,656 shares of Centessa Pharmaceuticals stock in a transaction on Monday, April 21st. The shares were sold at an average price of $12.29, for a total value of $180,122.24. Following the completion of the transaction, the chief executive officer now owns 261,361 shares of the company's stock, valued at approximately $3,212,126.69. This trade represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Saurabh Saha also recently made the following trade(s):

• On Thursday, March 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.69, for a total value of $917,950.00.
• On Thursday, February 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.93, for a total value of $876,150.00.

Centessa Pharmaceuticals Stock Performance

NASDAQ CNTA traded up $0.18 during trading hours on Friday, hitting $13.79. The company had a trading volume of 480,936 shares, compared to its average volume of 607,292. The business has a 50 day moving average of $14.42 and a 200-day moving average of $15.87. The company has a market cap of $1.84 billion, a PE ratio of -9.01 and a beta of 1.53. Centessa Pharmaceuticals plc has a 1-year low of $7.75 and a 1-year high of $19.09. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.38) by $0.04. As a group, equities research analysts expect that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Analyst Upgrades and Downgrades

CNTA has been the subject of a number of recent research reports. Guggenheim reiterated a "buy" rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating for the company. Piper Sandler assumed coverage on Centessa Pharmaceuticals in a report on Monday, March 31st. They issued an "overweight" rating and a $38.00 target price on the stock. Finally, Morgan Stanley reaffirmed an "overweight" rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $27.71.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. GF Fund Management CO. LTD. acquired a new stake in Centessa Pharmaceuticals during the 4th quarter worth $31,000. GAMMA Investing LLC boosted its stake in shares of Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock worth $64,000 after buying an additional 865 shares during the period. Barclays PLC boosted its stake in shares of Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after buying an additional 4,952 shares during the period. BNP Paribas Financial Markets purchased a new position in shares of Centessa Pharmaceuticals during the fourth quarter worth about $162,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in Centessa Pharmaceuticals in the 4th quarter valued at about $171,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.